Stryker (SYK) has registered strong results over the last few quarters and has been expanding at a fast pace through organic and inorganic growth. The company has made a number of acquisitions and expanded its market presence across product lines and regions. Its most recent earnings results were reported on October 26, 2017. For details, read Stryker’s 3Q17 Sales Exceed Estimates despite Recent Headwinds.
In this part, we’ll look at analysts’ recent ratings, recommendations, and target prices for Stryker. As of December 18, 2017, according to a Reuters survey of 27 brokerages and investment research companies, Stryker was rated “buy” by 17 companies, “hold” by 14, and “sell” by two.
The above chart shows recommendations for Stryker. As of December 18, 2017, the consensus target price for Stryker for an investment over the next 12 months was $160.30, representing a potential return of ~3.9% based on SYK stock’s closing price of $154.20 on December 15, 2017.
On December 7, 2017, Needham & Company reissued its “hold” rating on SYK stock. The company believes Stryker’s recent acquisition of Entellus Medical is a good deal from a strategic and financial perspective. It expects the deal to be accretive to Stryker’s growth in the years ahead. Needham & Company had maintained its “hold” recommendation on the stock on November 3, 2017, as well. For exposure to Stryker, investors could consider the Vanguard S&P 500 ETF (VOO), which has a ~0.22% exposure to SYK.